We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: diabetes
MedXY News
EnglishTag

diabetes

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial
Diabetes & Endocrinologyclinical trialdiabetes

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial

By MedXY|Dec 13, 2025

This clinical trial evaluated monthly grocery vouchers for improving diabetes control in food-insecure patients, finding increased self-reported fruit and vegetable intake but no significant HbA1c improvement.

Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy
Diabetes & Endocrinologydiabetesmetformin

Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy

By MedXY|Nov 17, 2025

A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.

Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults
Diabetes & Endocrinologydiabetesneurodegeneration

Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults

By MedXY|Nov 4, 2025

A pan‑European analysis (n=5,550) found diabetes was associated with lower odds of amyloid and p‑tau pathology in cognitively impaired patients, but with markers of neurodegeneration (total tau, medial temporal atrophy) in cognitively norma

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study
Dermatologyatopic dermatitisdiabetes

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

By MedXY|Nov 1, 2025

A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.

Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program
AIartificial intelligencediabetes

Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program

By MedXY|Oct 29, 2025

This review examines the first phase 3 randomized trial demonstrating that an AI-powered Diabetes Prevention Program lifestyle intervention is noninferior to human coaching in improving weight loss, HbA1c, and physical activity among adults

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis
Cardiologycardiovascular riskCoronary heart disease

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

By MedXY|Oct 19, 2025

This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes sta

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes
Clinical UpdatesADA 2024diabetes

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

By MedXY|Oct 9, 2025

The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
Cardiologyatrial fibrillationdiabetes

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY|Oct 7, 2025

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care
Diabetes & EndocrinologyADA 2024diabetes

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

By MedXY|Oct 6, 2025

A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.

Impact of Maternal Trace Element Levels on Neonatal Growth Among Diabetic and Non-Diabetic Pregnancies
Diabetes & EndocrinologydiabetesPregnancy

Impact of Maternal Trace Element Levels on Neonatal Growth Among Diabetic and Non-Diabetic Pregnancies

By MedXY|Oct 5, 2025

A case–control study reveals that elevated copper levels in diabetic pregnant women negatively affect newborn weight and head circumference, while chromium correlates positively with birth length. Smoking exposure adversely impacts infants’

Recent Advances in Cinnamon and Its Extracts: Clinical Applications and Therapeutic Potentials Across Metabolic, Cardiovascular, Cognitive, and Infectious Diseases
Cardiologycardiovascular riskCinnamon

Recent Advances in Cinnamon and Its Extracts: Clinical Applications and Therapeutic Potentials Across Metabolic, Cardiovascular, Cognitive, and Infectious Diseases

By MedXY|Oct 4, 2025

A decade of research highlights cinnamon’s benefits in glycemic control, lipid modulation, anti-inflammatory effects, cognitive enhancement, and antimicrobial activity, supporting its adjunctive clinical use and revealing promising th

Preventive PCI for Vulnerable Non-Flow-Limiting Coronary Plaques in Diabetes: Insights from the PREVENT Trial
CardiologyCoronary Interventiondiabetes

Preventive PCI for Vulnerable Non-Flow-Limiting Coronary Plaques in Diabetes: Insights from the PREVENT Trial

By MedXY|Oct 4, 2025

The PREVENT trial demonstrates that preventive PCI reduces adverse cardiac events in patients with vulnerable, non-flow-limiting coronary plaques, regardless of diabetes status, supporting a proactive interventional strategy alongside medic

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care
Diabetes & EndocrinologyADA 2024CGM

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

By MedXY|Oct 4, 2025

A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care
Diabetes & EndocrinologyADA 2024continuous glucose monitoring

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care

By MedXY|Oct 4, 2025

The ADA’s 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.

Global Impact of Cardiovascular Risk Factors on Lifetime Cardiovascular Disease Burden and Mortality: A Comprehensive Evidence Synthesis
Cardiologycardiovascular riskdiabetes

Global Impact of Cardiovascular Risk Factors on Lifetime Cardiovascular Disease Burden and Mortality: A Comprehensive Evidence Synthesis

By MedXY|Oct 4, 2025

This review integrates data from over two million individuals globally, showing that absence of five key cardiovascular risk factors at age 50 confers a life expectancy advantage exceeding a decade, with midlife modification of hypertension

Recent Advances in High-Intensity Interval Training: Cardiovascular, Metabolic, Diabetes, and Neuroprotective Effects
Cardiologycardiovascular healthdiabetes

Recent Advances in High-Intensity Interval Training: Cardiovascular, Metabolic, Diabetes, and Neuroprotective Effects

By MedXY|Oct 3, 2025

This review synthesizes recent evidence on the benefits of high-intensity interval training (HIIT) on cardiovascular health, diabetes management, metabolic function, and neuroprotection, highlighting mechanistic insights and clinical implic

Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients
Clinical Updatesage-related macular degenerationdiabetes

Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients

By MedXY|Oct 3, 2025

A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.

SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes
Clinical Updatesdiabetesmortality risk

SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes

By MedXY|Oct 3, 2025

Recent research indicates that patients with type 2 diabetes who use SGLT2 inhibitors after a urinary tract infection have a lower mortality risk compared to those using DPP-4 inhibitors.

Improving Patient Safety: The Role of Deprescribing Diabetes Medication in Older Adults
Diabetes & Endocrinologydeprescribingdiabetes

Improving Patient Safety: The Role of Deprescribing Diabetes Medication in Older Adults

By MedXY|Oct 2, 2025

This study examines the effectiveness of physician academic detailing combined with previsit patient activation to increase diabetes medication deprescribing amongst older adults, aiming to reduce hypoglycemia-related complications.

Diabetic Peripheral Neuropathy as a Predictor of Lacunar Stroke in Diabetes Patients
Diabetes & EndocrinologydiabetesDiabetic peripheral neuropathy

Diabetic Peripheral Neuropathy as a Predictor of Lacunar Stroke in Diabetes Patients

By MedXY|Oct 2, 2025

A study reveals diabetic peripheral neuropathy (DPN) significantly associates with cerebral small-vessel disease (SVD), indicating a predictive role for lacunar stroke in diabetic patients and highlighting opportunities for early interventi

Prev
3 / 4
1234
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities